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Urodilatin, not nitroprusside, combined with dopamine
reverses ischemic acute renal failure
SIDNEY SHAW, PETER WEIDMANN, and ARTHUR ZIMMERMANN
University of Bern, Medizinische Poliklinik and Department of Pathology, Inselspital, Bern, Switzerland
Urodilation, not nitroprusside, combined with dopamine reverses iseh-
emic acute renal failure. The present study was undertaken to: (a) clarify
the comparative renal potency of bolus injection of the natriuretic
peptides urodilatin and ANF'26 in the rat; (b) establish whether or not
intravenous (i.v.) infusion of urodilatin (200 ng/min) combined with
dopamine (UD) to maintain mean arterial pressure could improve GFR
or renal histology in established experimental ischemic acute renal
failure (ARF) induced by 30 minutes of bilateral renal artery clamping;
(c) assess comparative efficacies of nitroprusside, an activator of
soluble guanylate cyclase, combined with dopamine (ND) or control
infusions of dopamine alone (DA), under equivalent conditions; and (d)
determine effects of intra-renal arterial infusions of the stable cGMP
analogue dibutyryl-cGMP immediately after renal artery clamping(RAC). After initial dose finding studies, i.v. infusion of UD 24 hours
after 30 minutes of RAC improved GFR over five hours from 0.24
0.04 to 1.0 0.16 mI/mm in association with a threefold rise in plasma
cOMP and a 13-fold increase in urinary cGMP excretion. Plasma
creatinine dropped by 41% from 230 16 to 135 18 SM/liter and was
still reduced 24 hours later with values averaging 106 14 compared to
274 53 .tM/Iiter in non-treated animals. During infusion, UV and
FENa+ increased from 1.4 0.2 to 8.3 mI/mm, and from 2.9 0.5 to
maximum values of 15.8 2.4%. ND or DA alone were less effective,
increasing GFR only to 14 and 20%, respectively, of normal values, but
improvements were not sustained; in contrast to UD, ND did not alter
plasma or urinary cOMP. In addition, DBcGMP was ineffective in
improving GFR during early ARF. Histologically UD, but not ND,
markedly reduced the incidence of granular casts, tubular desquama-
tion and tubular necrosis in cortical areas and increased the incidence of
medullary mitoses.
Experimental acute renal failure (ARF) of ischemic or toxic
origin may be effectively attenuated by atrial natriuretic factor
(ANF'26) or certain synthetic analogues administered before
or early after the onset of renal injury [1—9]. Nevertheless, these
atrial peptides also tend to lower systemic blood pressure (BP)
which can, in turn, antagonize a beneficial influence on ARF.
This problem has been circumvented by infusing the peptides
either directly into the renal artery [2] or, when applied intra-
venously, by concomitant administration of dopamine to main-
tain BP [10]. Most recently, administration of atriopeptin III
combined with dopamine was reported to improve renal func-
tion in uninephrectomized rats with norepinephrine-induced
ARF treated as late as two days after disease onset [11].
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Urodilatin is a natriuretic peptide of presumed renal origin.
Its structure comprises the entire sequence of human ANF'26
plus a four-amino-acid N-terminal extension [12], but in con-
trast to ANF99'26 it has been reported in some species to be
resistant to degradation by renal cortical atriopeptidase EC
3.4.24.11 [13]. Administered systemically to humans with nor-
mal kidney function, urodilatin displays only a minimal hy-
potensive effect, but exceeds ANF'26 in increasing GFR,
natriuresis and urinary excretion of cyclic GMP (cGMP) [14].
Moreover, urodilatin rather than AN F99'26 may be the member
of the ANF family primarily involved in the regulation of
diuresis and sodium excretion [15, 16]. Actions of urodilatin, as
well as ANF'26 and synthetic atrial peptide analogues, seem
to involve activation of particulate guanylate cyclase and gen-
eration of cGMP as a second messenger [14, 16—191, suggesting
that increased cGMP could represent a key step resulting in
improvement of ARF. In vitro studies have shown that other
agents which stimulate production or otherwise raise intracel-
lular cGMP concentrations can often simulate effects of natri-
uretic peptides [20]. Whether urodilatin and/or other modula-
tors of cGMP are able to modify established ischemic ARF has
been unknown. The present study was undertaken, therefore,
to determine: (a) whether systemically administered urodilatin
combined with dopamine can improve established postischemic
ARF induced 24 hours earlier in bilaterally renally-intact rats by
renal artery occlusion (a model of ARF with distinct clinical
parallels which avoids partial protective effects of prior unine-
phrectomy [2]); (b) comparative effects of nitroprusside, an
activator of soluble guanylate cyclase [19], combined with
dopamine or of a control infusion of dopamine alone in the same
type and stage of ARF; and (c) effects of raising extracellular
cGMP levels, by intrarenal-arterial infusion of the stable ana-
logue dibutyryl-cGMP (DBcGMP), immediately after renal ar-
tery clamping, that is, in a less severe model of ARF with
previously demonstrated efficacy of AN F99'26 [2].
Experiments with urodilatin in postischemic ARF were pre-
ceeded by a dose-effect finding study in normal rats to establish
relative potencies of intravenously administered urodilatin and
ANF99'26 in increasing C'4-inulin clearance rates (GFR) and
excretory renal function. Results showed the two peptides in
these circumstances to be essentially equipotent, and since
effects of ANF have previously been examined under similar
conditions [11], only urodilatin responses were compared to
nitroprusside and dopamine in the present study.
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Methods
Comparative study of renal response to urodila tin or
ANF-99'26 in normal rats
Comparative effects of bolus intravenous injection of urodil-
atm and ANF99 126 were evaluated in separate groups of Spra-
gue-Dawley rats under pentobarbital anaesthesia. After implan-
tation of carotid, jugular vein, and bladder cannula, a two-hour
equilibration period was allowed before beginning each exper-
iment. Effects of ANF99'26 or urodilatin on C'4-inulin clearance
(GFR), fractional excretion of sodium (FENa) and potassium
(FEK.) and urine volume (UV) were monitored for 60 minutes
following injection of 1, 2 or 3.5 sg/kg of the peptides in
separate animals. Maximum responses occurring approxi-
mately 10 minutes after injection were recorded.
Studies in established acute renal failure
Surgical procedures.All experiments were performed on 300 g
Sprague-Dawley rats under pentobarbital anaesthesia. Since
bilaterally renally-intact animals in the established phase of
ARF were anticipated to display a greatly enhanced severity of
renal impairment, due to a markedly compromised intravascu-
lar volume and more extensive renal necrosis, a clamp time of
30 minutes was used in the present studies [2]. Briefly, 24 hours
after 30 minutes of bilateral renal artery occlusion at 37.5°C,
carotid artery, jugular vein and bladder cannula were inserted,
and separate groups of animals (N = 6) received five-hour
intravenous infusions of either (a) synthetic urodilatin acetate
(BissendorfPeptide GmbH, Wedemark, Germany) (200 ng/min,
0.67 g/kg/min) plus dopamine at a mean dose of 0.08 0.0 14
mg/kg/mm sufficient to maintain mean arterial pressure (MAP)
at 112 1 mm Hg (UD group), (b) an equi-depressor dose of
nitroprusside (7 g/kg/min), (which, without dopamine, low-
ered MAP by 25 2 mm Hg similar to the drop in MAP
produced by urodilatin alone), combined with dopamine at a
mean dose of 0.07 0.014 mg/kg/mm (MAP 108 4 mm Hg,
ND group), or (c) dopamine alone (8 sg/kg/min) (MAP 115 3
mm Hg, DA group). Higher doses of nitroprusside could not be
assessed because of uncontrollable hypotension. Mean arterial
pressure (MAP), plasma creatinine, cGMP (RIA kit Amer-
sham), GFR, UV, FENa and FEK* and urinary cGMP excre-
tion were monitored. Urinary losses were measured every 15
minutes and replaced by infusion of 0.9% saline into the left
jugular vein. After the five hour infusion the bladder was
sutured and animals were allowed to recover. Adequate hydra-
tion was maintained by intermittent subcutaneous administra-
tion of isotonic glucose. Forty-eight hours after induction of
ARF, plasma creatinine was again measured and the left kidney
fixed in 10% formalin for semi-quantitative histological evalua-
tion. In a separate non-treated group of animals plasma creati-
nine levels were measured 48 hours after similar induction of
ARF.
Histological evaluation .Using a Neofluar 40x objective and
lOx eyepiece, 20 high power fields in both the renal outer
cortex and non-papillary medulla from hematoxylin and eosin
stained paraffin sections were randomly chosen in each prepa-
ration. In every high power field, each of the following events
were counted: (a) tubular cell desquamation identifiable as
intact or damaged epithelial cells within the tubular lumen; one
tubule lumen containing such cells was counted as one event;
(b) tubular necrosis defined as a focus of necrotic tubular cells
with nuclear debris, with or without granulocytic reaction; (c)
protein casts identifiable as homogeneous eosinophilic luminal
deposits; (d) granular casts distinguishable from above by a
granular appearance and probably comprised of proteins to-
gether with cell debris; (e) mitoses, as evidenced by the mitotic
figures of tubular epithelial cells, (I) medullary hyperemia which
was graded according to the scores, "0" = no hyperemia, "1"
= hyperemia involving less than one quarter of the area of a
high power field, "2" = hyperemia involving between one
quarter and half the area of one high power field, "3" =
hyperemia involving more or less the whole area of a high
power field. In this way, 480 high power fields were analyzed in
a total of 12 kidneys from UD and ND treated animals.
Evaluation of effects of intrarenal dibutyryl-cyclic-GMP in
early ARF
These experiments were performed with the knowledge that
nitroprusside with dopamine was ineffective in attenuating
established ARF. Hence the initial protocol for this part of the
study was modified in an attempt to optimize conditions for
detecting any possible effect of other ways of manipulating
cellular cGMP levels, that is, administering DBcGMP at the
early stages in a potentially more readily reversible model of
ARF using previously uninephrectomized, one hour-clamped
rats and an experimental protocol with previously demon-
strated efficacy of ANF'26 [2]. Since these results were also
negative, no further attempt was made to evaluate effects of
DBcGMP in established ARF. Surgical procedures were similar
to previously described protocols [2] except that after renal
artery clamping DBcGMP in 0.9% saline was infused in-
trarenally for four hours (42 g/kg/min). Indices of renal func-
tion were monitored during the last hour of infusion. Sham
animals were similarly infused but the renal artery was not
clamped.
Statistics
Statistics were performed using the Statistical Analysis Soft-
ware Package (version OS 5.0 SAS Institute Cary, North
Carolina, USA) and Apple Macintosh Systems. Tests included
analysis of variance for intra-group differences between initial
and final values of MAP, GFR, cGMP, creatinine and UV, or
Bonferroni-Dunn tests for inter-group differences between
these parameters. Non-parametric Wilcoxon scores were used
to assess differences between FENa and FEK+ and histological
variables outlines above. A level of P < 0.05 was chosen as the
criterion for significance. All values are presented as mean
standard error of the mean.
Results
Comparative effects of urodilatin and ANF99'26
Intravenous bolus injection of ANF99'26 or urodilatin pro-
duced dose dependent increases in GFR, FENa, FEK' and UV
(Table 1). MAP or hematocrit were unchanged. Maximum
responses at 10 minutes or integrated responses over one hour
after injection did not differ significantly between given bolus
doses of urodilatin or ANF'26. On this basis, together with
the expectation of uremia-induced blunting of the renal re-
sponse, an infusion rate of 200 ng/min/animal (0.67 g/kg/min)
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Table 1. Comparative effects of bolus intravenous injections of I, 2,
and 3.5 tg/kg of ANF'26 and urodilatin on C'4-inulin clearance
(GFR), urine volume (UV) and fractional excretion of sodium
(FEN) and potassium (FEK) in normal Sprague-Dawley rats
under nembutal anesthesia (mean sEat)
Dose GFR uv — FEN FEK1
_________pg/kg ml/min/100 g mi/hr — %
ANF99'26 0 0.97 0.1 0.7 0.2 0.18 0.07 21 2
1.0 1.6 O.l' 2.6 0.7 0.8 0.2" 17 I
2.0 1.7 0.2" 2.7 0.54" 1.5 0.3" 26 I
3.5 2.0 0.2" 4.0 0.93" 2.0 0.5" 25 3
Urodilatin 0 0.96 0.04 0.6 0.1 0.18 0.05
1.0 1.7 0.1" 1.4 0.15" 0.6 0.l
2.0 1.7 0.2" 2.0 0.35" 1.1 0.3a
3.5 1.8 0.2" 3.9 0.9" 1.6 0.3"
"P < 0.05 compared to '0' dose values
Time, hours
Fig. 1. Progressive improvement in C'4-inulin clearance during a five-
hour intravenous infusion of urodilatin combined with dopamine (A,
UD), nitroprusside combined with dopamine (•, ND) or dopamine
alone (0, DA), during established experimental acute renal failure in
the rat induced by 30 minutes of renal artery clamping. * P < 0.0001,
P < 0.01 and P < 0.05 compared to pre-infusion.
was chosen as an optimum dose for intravenous infusion of
urodilatin administration in established ARF.
Studies in established ARF
Twenty-four hours after renal ischemia induced by 30 min-
utes of bilateral renal artery occlusion GFR, estimated by
C'4-inulin clearance, was severely reduced in all study groups
to an average of 0.20 0.02 mI/mm (approximately 7% of the
normally measured value in our laboratory for none clamped
animals under nembutal anaesthesia of 2.8 0.03 mI/mm, N =
50). Plasma creatinine was elevated to 231 10 jiM/liter
(compared to normal values of 52 I jiM/liter).
During the infusion, GFR steadily increased in the UD group
from 0.24 0.04 to 1.0 0.16 mI/mm (P < 0.0001; Fig. 1). This
increase to 36% of normal values was greater (P < 0.0001) than
the tendency for slight GFR changes in either the DA group
0
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C
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Fig. 2. Plasma crealinine levels in established ischemic acute renal
failure during a five-hour intravenous infusion and 24 hours after the
end of infusion in animals receiving urodilatin combined with dopa-
mine, (A, UD) nitroprusside combined with dopamine (I, ND), dopa-
mine alone (0, DA) or no treatment (0, NT). * P < 0.001 compared to
DA, ND and NT groups.
treated animals). In non-treated animals, corresponding plasma
creatinine levels 48 hours after renal ischemia averaged 274
22 jiM/liter (P < 0.0001 vs. UD, not significant vs. DA or ND).
During the five-hour infusion period, diuresis increased upon
administration of UD from 1.4 0.2 to 8.3 0.8 mllhr at the
end of the infusion (P < 0.0001; Fig. 3). This markedly
exceeded (P <0.0001) a tendency for slight changes in diuresis
with DA (from 1.0 0.2 to 3.0 0,6 ml/hr, not significant) or
ND (from 0.9 0.1 to 3.1 0.1 ml/hr, P < 0.01). The volumes
of urine output and 0.9% saline infused to balance it in the UD,
ND and DA groups over the time of infusion averaged 45 3
vs. 44 3 ml, 14 0.6 ml vs. 13 0.7 ml and 15.5 I vs. 13
1.5 ml, respectively.
Urinary FENU+ increased from 2.9 0.5 to 15.8 2.4%
within the first two hours of UD (P < 0.05) and remained
approximately fourfold above pre-treatment values during the
remainder of this infusion (P < 0.05, Fig. 4A). ND (P < 0.05) or
DA (not significant) produced a more gradual and less pro-
nounced rise in FENU+. Urinary FEK+ decreased significantly
during UD (P < 0.05) but not with ND or DA (Fig. 4B).
Twenty-four hours after renal ischemia, plasma cGMP levels
were within the normal range of 8.4 2.7 pmol/ml but urinary
250-
200-
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20 2
21 2
24 I
24 3 I I I I ' I
0 1 2 3 4 5 24
E
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[from 0.21 0.04 to 0.57 0.02 mI/mm, P < 0.01 (20% of
normal)] or the NP group [from 0.20 0.03 to 0.4 0.05
mi/mm, P < 0.05 (14% of normal)].
Plasma creatinine progressively decreased during the five
hour infusion of UD from 230 16 to 135 18 jiM/liter (P <
0.0001, Fig. 2). This decrease was more pronounced (P <0.001)
than tendencies for changes during administration of DA (from
221 4 to 165 6 jiM/liter, not significant) or ND (from 237
23 to 195 21 jiM/liter, not significant). Nineteen hours after
0 1 the end of these infusions (that is, 48 hr after renal ischemic
injury), plasma creatinine was improved further in the UD
group (106 14 jiM/liter, P < 0.0001), but rose again to
pre-treatment values in the groups receiving DA (210 16
jiM/liter) or ND (230 34 jiM/liter not significant from non-
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cGMP excretion was markedly decreased from normal values
of 1.9 0.2 to 0.13 0.022 nmol/hr. During the five-hour
infusion period, UD increased plasma cGMP approximately
fourfold to 34 3 pmol/ml and acutely restored urinary cGMP
excretion to 2.1 0.26 nmol/hr within the first hour and an
average of 3.0 0.3 nmol/hr during the rest of the five hour
infusion. ND infusion did not change plasma levels or urinary
excretion of cGMP, which remained stable at 8.9 1 pmol/ml
and 0.22 0.03 nmol/hr, respectively, throughout the five-hour
infusion (Fig. 5).
During the five-hour infusion period, MAP averaged 112 1
mm Hg with UD and DA, compared with pre-infusion values of
119 2 mm Hg. However, during the three minutes before the
start of the dopamine titration, urodilatin (0.67 g/kg/min)
decreased MAP by 22 3 mm Hg (P < 0.001). During infusion
of ND with DA, MAP averaged 109 4mm Hg compared with
pre-infusion values of 115 3 mm Hg. DA alone tended to raise
MAP from 113 3 to 118 2 mm Hg for the first two hours,
thereafter MAP stabilized at 116 4 mm Hg. Although MAP
tended to be slightly higher in the DA group, differences
between or within groups were not statistically significant.
Histological assessment
Renal cortical and medullary tissue were analyzed in the UD
and ND groups, that is, the most and the least effective
pharmacological interventions, respectively, with regard to
GFR and plasma creatinine. Based on Wilcoxon scores, the UD
group had significantly less (P < 0.05) cortical tubular cell
desquamation (10.5 2.6 vs. 21.2 3.9) and necrosis (0.17
0.02 vs. 1.2 0.07) or granular casts in cortex (8.7 2.6 vs.
26.2 4.9) and medulla (11.3 2.0 vs. 23.3 3.9; Fig. 6).
Conversely, the incidence of mitoses in medulla was higher (P
<0.05) in the UD than in the ND group. Medullary hyperemia,
A UD DN DA
rrrffl
012345 012345 012345
Time, hours
Fig. 4. Fractional excretion of sodium (A) and potassium (B) in re-
sponse to a five-hour systemic infusion of urodilatin combined with
dopamine (UD), nitroprusside combined with dopamine (ND) or
dopa,nine alone (DA) 24 hours after 30 minutes of bilateral renal artery
clamping in the rat. * P < 0.05 compared to initial values.
the incidence of protein casts or other analyzed features were
not differentially affected by the two treatments.
Assessment of potential therapeutic efficacy of DBcGMP in
early ARF
A four-hour intra-renal arterial infusion of DBcGMP admin-
istered immediately after renal artery clamping in uninephrec-
tornized animals at a dose which, in normal rats, produces a
two- to threefold increase in UV and FENa* did not modify
plasma creatinine levels or creatinine clearance rates measured
four hours or 24 hours after infusion in animals with ARF
compared to saline infused controls (Table 2).
Discussion
These findings in bilaterally renally-clamped animals demon-
strate that urodilatin can markedly improve ischemia-induced
acute renal failure after the latter has already been established
for 24 hours. Initiated at this advanced stage, an infusion of
urodilatin combined with dopamine gradually restored GFR
over five hours from 7 to 36% of normal, decreased plasma
creatinine from 230 16 to 135 18 xM/liter, and increased
urinary FENa and urine flow four to fivefold (P < 0.05 to
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Fig. 3. Urine flow in response to a five-hour systemic infusion of
urodilatin (A, UD) combined with dopamine, nitroprusside combined
with dopamine (•, ND) or dopamine alone (0, DA), 24 hours after 30
minutes of bilateral renal artery clamping in the rat. * P < 0.0001
compared to ND and DA treated groups.
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Fig. 5. Urinary and plasma cGMP values during a four- to five-hour
intravenous infusion of urodilatin combined with dopamine (A, UD) or
nitroprusside combined with dopamine (•. ND) in established experi-
mental ischemic renal failure induced by 30 minutes of renal artery
clamping in the rat. * P < 0.0001 compared to ND group or pre-infusion
values.
0.0001); moreover, improvement in renal function was sus-
tained 48 hours after injury, as evidenced by continued reduc-
tion in plasma creatinine to 106 14 MM/liter (P < 0.0001). In
contrast, infusions of nitroprusside combined with dopamine or
control infusions of dopamine alone were distinctly less effec-
tive (P < 0.05 to 0.001), producing only mild and transient renal
functional changes which, after cessation of infusion reverted
with renewed rises in plasma creatinine to 210 16 and 230
34 JLM/liter, respectively, 48 hours after initiation of renal
ischemia. These values do not differ significantly from the
48-hour plasma creatinine value of 274 22 SM/liter in control
animals undergoing similar renal artery clamping but receiving
no treatment.
The distinct therapeutic efficacy of urodilatin in established
acute renal failure is further evidenced by the renal histological
findings 48 hours after ischemic injury. Compared with the
nitroprusside-dopamine combination, urodilatin combined with
dopamine significantly reduced tubular granular casts, cortical
tubular cell desquamation and necrosis and increased medullary
tubular cell mitoses. On the other hand, the incidence of
Fig. 6. Semiquanfitative evaluation of histological indices in cortex
and medulla 24 hours after a five-hour systemic infusion of urodilatin
combined with dopamine () or nitroprusside combined with dopamine
(•) during the established phase of experimental ischemic acute renal
failure in the rat induced by 30 minutes of renal artery occlusion. The
evaluation records the mean SEM of the number of events in 120
randomly chosen high power fields in each area from a total of 12
kidneys. * P < 0.05 between groups.
medullary hyperemia [21], which can be improved by an early
four-hour intrarenal arterial ANF'26 infusion [2], was not
differentially affected by the two treatments.
The functional and morphological improvement in postisch-
emic kidneys could not be explained as a non-specific conse-
quence of different degrees of renal damage before pharmaco-
logical intervention or treatment-associated differences in the
state of hydration or systemic BP. Thus, the three intervention
groups were similar with regard to pre-treatment GFR and urine
flow; urinary fluid losses during infusions were replaced
steadily and in even quantity. Infusions of urodilatin or nitro-
prusside combined with dopamine were accompanied by similar
mild decreases in MAP (on average 7 and 6 mm Hg, respec-
tively), which may have tended to antagonize a beneficial renal
effect of these two interventions, while MAP with dopamine
alone was if anything slightly increased.
Actions of the ANF family, to which urodilatin belongs,
involve cGMP as second messenger [17]. ANF'26 and its
analogues are thought to activate a particulate isoenzyme form
of guanylate cyclase which is an integral part of the 130 kD
ANF receptor [18]. Locations of this receptor type in the
kidney include afferent arterioles, glomeruli, outer medullary
vasa recta, inner medulla and arcuate arteries [22, 23]. In
contrast to ANF analogues, nitroprusside activates a soluble
form of guanylate cyclase 1191, thereby eliciting generalized
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increases in intracellular cGMP, while intravenous dopamine
has no known direct stimulatory influence on renal cGMP
production [24].
In the present study, urodilatin but not nitroprusside or
dopamine administration in established ARF normalized the
depressed urinary cGMP excretion and elevated cGMP levels in
the circulation. The severe reduction in cGMP excretion 24
hours after ischemic renal injury is commensurate with the fall
of GFR to 7% of normal. The approximately 24-fold rise in
urinary cGMP excretion induced by urodilatin during hours two
to four of the infusion is striking, its magnitude distinctly
exceeding the concomitant 15-fold increase in the filtered load
or four- to fivefold increases in UV and FENa*. This most likely
reflects urodilatin receptor-mediated intrarenal generation of
cGMP which appears to be closely associated with the progres-
sive restoration of renal function. Conceivably, the lack of
similar cGMP responses during nitroprusside infusion could
relate to the fact that extracellular or intracellular cGMP levels,
particularly in renal tissue, may not have been elevated to the
same extent as urodilatin even by this high dose of nitroprus-
side. Unlike in vitro studies, however, effects of higher doses
could not be adequately assessed due to an inability to control
the marked decrease in MAP. While the present data do not
exclude the former possibility results are also consistent with
previous reports suggesting that activation of particulate but not
soluble guanylate cyclase increases extracellular cGMP extru-
sion [25]. Nevertheless, the relevance of extracellular cGMP
overflow per se for the therapeutic efficacy of urodilatin as
compared with nitroprusside in ARF is questionable, since
intrarenal arterial infusion of DBcGMP in uninephrectomized
animals immediately after renal artery clamping, that is, at a
time when ANF99 126 administration restored renal function [2],
failed to improve this type of postischemic ARF despite signif-
icant effects on UV and FENO+.
More relevant mechanisms underlying the difference between
urodilatin and nitroprusside could relate to the fact that urodil-
atm like ANF may have selective tubular and vascular effects,
whereas nitroprusside is primarily a vasoactive agent with a
nonselective site of action. At the renal hemodynamic level,
nitroprusside and dopamine act as general vasodilators [19, 26],
while ANF administered in high doses preferentially dilates
afferent and/or constricts efferent glomerular arterioles, thereby
increasing glomerular filtration pressure [27]. The latter may
well be a primary prerequisite for functional improvement of
ARF. although the relative additional therapeutic contribution
of concomitant glomerular or other renal hemodynamic and
tubular actions of ANF9'26 and urodilatin [28] requires further
clarification.
ANF99126 and urodilatin seem to exert qualitatively similar
effects on renal function, as noted in the present assessment in
normal rats and our previous study in normal humans [14].
Nevertheless, in humans urodilatin injected in a modest dose of
50 p.g was twice as effective as ANF99'26 in increasing diuresis,
natriuresis and cGMP excretion [14], while at the high doses
administered to the rats, urodilatin dose dependently and com-
parably increased UV, FENa' and GFR. In ARF, increased
GFR and tubular fluid flow rates may, by gradual washout of
tubular debris, relieve tubular obstruction and, by lowering
intratubular pressure, also reduce transtubular backleak of
filtrate. Indeed, the incidence of granular casts, particularly in
cortical regions was lowered following treatment of ARF with
urodilatin combined with dopamine.
Renal perfusion pressure is an important co-determinant of
the influence of ANF99'26 [7] and presumably also urodilatin on
renal function. Therefore, the therapeutic potential of high
doses of ANF'26 or urodilatin in ARF rests on the prerequi-
site that systemic BP is not decreased concomitantly beyond a
certain degree, which occurs when high ANF99'26 doses are
administered intravenously [3]. To circumvent this problem,
experimental ARF has been treated successfully by infusing
ANF99'26 either directly into the renal artery [2] or intrave-
nously in combination with dopamine [10, 111. Systematically
administered urodilatin may at least in normal humans prove to
99-I'6be less hypotensive than ANF [14]. Nevertheless, in the
rats with postischemic ARF, MAP fell immediately after the
start of systemic urodilatin infusion and required subsequent
titration with dopamine to limit the decrease from an initial 22 to
7 mm Hg. The slightly improved GFR in association with an
initial increase in MAP during infusion of dopamine alone, and
the lack of a significant GFR change during infusion of higher
dopamine doses combined with nitroprusside at a similarly
reduced MAP as the urodilatin-dopamine combination group,
further suggest a modulatory influence of systemic BP.
Finally, an additional contribution of dopamine beyond sys-
temic hemodynamic maintenance to the therapeutic effect of
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Table 2. Effects of four-hour intrarenal arterial infusions of dibutyryl cGMP (DB cGMP) or 0.9% saline on indices of renal function, and mean
arterial pressure in uninephrectomized pentobarbital anesthetized normal Sprague-Dawley rats (Sham) and those with ARF (experimental)
induced by 60 minutes of renal artery clamping (RAC) (mean SE)
Sham (No. RAC)
3—4hr 3-.4hrDB
saline cGMP
infusion infusion
Experimental (RAC)
3—4 hr 3—4 hr DB 24 hr after
saline cGMP DB cGMP
infusion infusion infusion
N 6
Plasma creatinine ,zM 41 4 44 2 115 l0 97 l2 272 70
Creatinine clearance mi/mi,, 0.89 0.15 0.81 0.04 0.1 0.0l 0.14 0.03 0.16 0.08k
Urine volume mI/hr 0.45 0.1 0.93 0.2a 2.1 0.4a 1.24 0.3 0.77 o.2
Fractional Na excretion % 0.6 0.2 2.54 0.68a 2.0 O.4 18.9 9 12.6 3
Mean arterial pressure nzmHg 98 2 107 5 100 3 98 3 109 9
6 6 6 6
Abbreviations are: RAC, renal artery clamping; DB cGMP, dibutyryl cyclic GMP.
a P < 0.05 compared to sham saline-infused controls
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the urodilatin-dopamine combination in postischemic ARF can-
not entirely be ruled out. In addition to reducing intrarenal
vascular resistance and increasing renal cortical perfusion [29,
30], dopamine has been reported to decrease basal mesangial
cell tone and its response to angiotensin II [31] and could,
through its vasodilatory action, promote delivery of urodilatin
to its sites of action and/or facilitate effects on filtration pressure
and GFR by increasing glomerular plasma flow [30].
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